Company · Healthtech & Bio

Origo Biopharma

origobiopharma.com ↗ ·Barcelona ·Seed

Origo Biopharma was a Spanish clinical-stage biotech founded in 2017 developing a platform of locally-acting, organ-restricted TGF-beta inhibitors for fibrosis and cancer, with lead programmes in Crohn's disease-associated fibrostenosis, idiopathic pulmonary fibrosis and colorectal cancer. It had research facilities in Touro (A Coruña, Galicia) and corporate offices in Barcelona, and raised a €2.3M Series Seed round led by Sabadell Asabys with XesGalicia and the founding shareholders. The company was acquired by Belgian biotech Agomab Therapeutics in October 2021 and now operates as Agomab Spain, so it is no longer an independent startup. Its founders have since launched a successor biotech, Iteria Biopharma (2024), which closed a €5M seed round in April 2026 with Inveready and XesGalicia.

Founded
2017
Founders
2
News
0
Rounds
1
Investors
3
SectorsBiotech, Pharmaceuticals, Drug Discovery, Fibrosis, Oncology, Life Sciences Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Profile updated 9 Aug 2026

Founders

Carme Pampín Casal
Co-founder (via GalChimia, where she is CEO & Founder)
Julio Castro-Palomino
Co-founder (Founder & CEO of Palobiofarma)

Global models

No comparables on record yet.

Investors 3

Asabys Partners (Sabadell Asabys Health Innovation Investments)
asabys.com
Investor Spain
Investor Spain
XesGalicia
www.xesgalicia.org
Investor Spain

Funding rounds 1

Seed · €2.3M
Origo Biopharma closed a €2.3M Series Seed round led by Asabys Partners through its Sabadell Asabys Health Innovation Investments fund, with…
2020-07-07

News & media

No coverage on record yet.
Start typing to search across everything.
↑↓ navigate↵ openesc close